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In 2015, the American Cancer Society estimates that 234,000 new
cases of breast cancer will be diagnosed along with an addi-
tional 60,000 cases of carcinoma in situ. Nearly 40,000 women
will die due to breast cancer annually (1). Current management
options for Stage 0, I, & II breast cancer include mastectomy,
breast conserving surgery (BCS), or breast conserving surgery fol-
lowed by whole breast radiation therapy (BCS+RT); the use of
chemotherapy is independent of local therapy. Coronary artery
disease (CAD) and cerebrovascular disease (CVD) are the first
and third leading causes of death, respectively, among men and
women in the United States (2). Patients with CVD share mul-
tiple common risk factors and lifestyle behaviors in addition to
frequently suffering from multiple comorbid conditions. Tobacco
use, hypertension, high cholesterol, diabetes, physical inactivity,
and poor nutrition are all established risk factors of heart disease.
The carcinogenic potential of antihypertensive medications has
been widely debated and while a meta-analysis found no increase
in cancer incidence or mortality, they could not rule this out with
certain combinations of drugs (3). In addition, as antihyperten-
sive medications for cardiovascular disease improve, patients are
living longer and are at greater risk for developing cancer. More-
over, patients with diseases such as breast cancer may develop CVD
from treatment, such as use of chemotherapy and radiation ther-
apy (RT). Inherently within these competing risks of morbidity
and mortality lays the intersection of the disciplines of cardiology
and oncology.
Cardio-oncology is a relatively new field which offers an inter-
disciplinary and integrative management approach to cancer
patients with cardiovascular risks specifically designed to miti-
gate risks of oncologic therapies and provide early detection and
treatment of those at greatest risk of cardio-toxicity. Given the
growing clinical relevance of cardio-oncology, this Frontiers in
Oncology Research Topic is focused on providing information to
practitioners in this quickly growing discipline. In this research
topic, Mookadam et al. eloquently frames the current practice in
cardio-oncology and provides future strategy and direction for
this novice field.
Effects on the heart are a potentially significant and serious
clinical problem in the treatment of breast cancer with RT. Over
the course of the past 50 years, there have been great advances
in the delivery of RT due to the development of new techniques,
beam energy, improvement in imaging modalities, and develop-
ment of image registration strategies. In this research topic, Yue
et al. and Chen et al. present novel techniques to track cardiac
motion during radiation treatments using fluoroscopy and cardiac
MRI, respectively (4, 5). In addition, Beck et al. reviews the various
radiotherapy treatment techniques used in breast cancer patients
to reduce cardiac dose (6). The study reported by Merino Lara
et al. attempts to translate the mean cardiac dose for various breast
radiotherapy techniques to the risk of a major cardiovascular event
(7). Finally, an editorial by Khan and colleagues expressively frames
the debate of cardiac irradiation into perspective (8).
It is hypothesized that cardiac damage from RT is correlated to
the dose absorbed by the heart and differs between left- and right-
breast radiotherapy. The damage to cardiac micro- and macro-
vasculature is the pathophysiological cause of RT-related heart
disease. Taunk and colleagues summarize the literature regard-
ing the underlying pathologic abnormalities and mechanisms of
RT-related heart disease (9).
Other manuscripts in this issue reflect the eclectic nature of
the field of cardio-oncology. Sharp and George review the poten-
tial benefit of stem cell therapy against cardio-toxicities from
breast cancer treatments, while Tian et al. review the literature of
serum biomarkers of cardiac toxicity after breast cancer treatments
(10, 11). Finally, Guo and Wong discuss cardiovascular toxici-
ties of chemotherapy and targeted therapies used in the systemic
treatment of breast cancer (12).
It is our hope that through this research topic, we may con-
tinue the dialog of reducing collateral damage to the cardiovascular
system by breast cancer therapies, both local and systemic. Guide-
lines regarding the prevention and treatment of cardiac toxicities
are scant and collaborative efforts are needed to facilitate their
development.
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